Cas12a is competitive for gene editing in the malaria parasites
Microbial Pathogenesis · 2025
DOI: 10.1016/j.micpath.2025.107340 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Pathogenesis, 2025. Verfasst von Shijie Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Anhui Medical University, Hefei, 230032, People's Republic of China. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems, Plasmodium, CRISPR-Associated Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: Scientific Research Foundation of Education Department of Anhui Province of China.
Abstract (Originalsprache)
Malaria, caused by the Plasmodium parasites, has always been one of the worst infectious diseases that threaten human health, making it necessary for us to study the genetic function and physiological mechanisms of Plasmodium parasites from the molecular level to find more effective ways of addressing the increasingly pressing threat. The CRISPR (Clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated protein) is an RNA-guided adaptive immune system, which has been extensively developed and used as a genome editing tool in many organisms, including Plasmodium parasites. However, due to the physiological characteristics and special genomic characteristics of Plasmodium parasites, most of the tools currently used for genome editing of Plasmodium parasites have not met expectations. CRISPR-Cas12a (also known as Cpf1), one of the CRISPR-Cas systems, has attracted considerable attention because of its characteristics of being used for biological diagnosis and multiple genome editing. Recent studies have shown that its unique properties fit the genetic makeup of Plasmodium parasites making it a promising tool for gene editing in these parasites. In this review, we have summarized the relevant content of the Cas12 family, especially the frequently used Cas12a, its advantages for gene editing, and the application prospects in Plasmodium parasites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Anhui Medical University, Hefei, 230032, People's Republic of China.
- Department of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, People's Republic of China.
- The First Clinical Medical College, Anhui Medical University, Hefei, 230032, People's Republic of China.
- The Second Clinical Medical College, Anhui Medical University, Hefei, 230032, People's Republic of China. Electronic address: 274466819@qq.com.
- Key Laboratory of Infection and Immunity of Anhui Higher Education Institutes, Bengbu Medical University, 2600 Donghai Avenue, Bengbu, Anhui, 233030, People's Republic of China. Electronic address: Taozhiyong@bbmc.edu.c…
- Department of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, People's Republic of China. Electronic address: happy2008con@aliy…
Förderung
- Scientific Research Foundation of Education Department of Anhui Province of China
Zitieren
APA
Yang, S., Wei, Y., Quansah, E., Zhang, Z., Da, W., Wang, B., Wang, K., Sun, D., Tao, Z., & Zhang, C. (2025). Cas12a is competitive for gene editing in the malaria parasites. Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2025.107340
Vancouver
Yang S, Wei Y, Quansah E, Zhang Z, Da W, Wang B, et al. Cas12a is competitive for gene editing in the malaria parasites. Microbial Pathogenesis. 2025. doi:10.1016/j.micpath.2025.107340
BibTeX
@article{Yang2025,
author = {Yang, Shijie and Wei, Yiming and Quansah, Elvis and Zhang, Ziyu and Da, Weiran and Wang, Bingjie and Wang, Kaige and Sun, Danhong and Tao, Zhiyong and Zhang, Chao},
title = {Cas12a is competitive for gene editing in the malaria parasites},
journal = {Microbial Pathogenesis},
year = {2025},
doi = {10.1016/j.micpath.2025.107340}
}
EUVIMED